Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Gains from Sales and Divestitures (2019 - 2021)

Phio Pharmaceuticals' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $2916.0 for Q3 2021.

  • For Q3 2021, Gains from Sales and Divestitures fell 22.9% year-over-year to $2916.0; the TTM value through Sep 2021 reached $2916.0, down 22.9%, while the annual FY2020 figure was $4282.0, 237.7% up from the prior year.
  • Gains from Sales and Divestitures reached $2916.0 in Q3 2021 per PHIO's latest filing, up from $2570.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $69750.0 in Q3 2019 to a low of $1268.0 in Q4 2019.
  • Average Gains from Sales and Divestitures over 3 years is $10440.8, with a median of $3403.0 recorded in 2020.
  • The largest YoY upside for Gains from Sales and Divestitures was 237.7% in 2020 against a maximum downside of 94.58% in 2020.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $1268.0 in 2019, then skyrocketed by 237.7% to $4282.0 in 2020, then tumbled by 31.9% to $2916.0 in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Gains from Sales and Divestitures are $2916.0 (Q3 2021), $2570.0 (Q2 2021), and $2570.0 (Q1 2021).